Winners, losers and the case for owning each

GMO’s Asset Allocation portfolios express three strongly held views: 1) value stocks globally are cheap relative to growth; 2) non-U.S. equity markets are cheap relative to the U.S.; and 3) traditional fixed income yielding less than inflation offers little benefit to portfolios. 

Recently, we’ve written extensively about the relative value opportunity for owning value stocks.(1) This quarter, we turn to our preference for owning stocks in non-U.S. markets. We look at the winners and losers of the last 10 years by analysing both the returns of equity markets and the fundamentals of the companies that comprise them. 

No one reading this quarterly will be surprised to see the U.S. equity market as the leading performer over the last decade, but some may be surprised to learn that Japanese companies delivered the best fundamental performance over that same period. 

We wrap up by considering the potential for last decade’s laggards to produce a better showing in the decade to come. Readers will see that non-U.S. markets are home to both winners and losers from the last 10 years while offering starting valuations that should position these markets to outperform the U.S. in the decade to come.

U.S. exceptionalism has been driven by multiple expansion

No review of equity market performance over the last decade can start without acknowledging just how strong performance has been for U.S. stocks. During the 10-year period from September 2011 to September 2021, the MSCI U.S. index grew at a 16% annualised pace, generating gains of nearly three and a half times capital. Over the same period, non-U.S. stocks, as measured by the MSCI All Country World ex-U.S. index, grew at less than half that pace (an otherwise respectable 7.5% annualised return) and delivered less than one-third of the gains of the U.S. market (see Exhibit 1).

Exhibit 1: The U.S. has had an extraordinary decade (as at 30/92021)

Source: MSCI, GMO analysis

Not only did the U.S. market simply trounce the rest of the world, its gains over this period also stand in stark contrast to its own performance during the preceding 10 years, especially when measured in real terms, that is after subtracting the rates of inflation during each time period.(2) From September 2011 to September 2021, the MSCI U.S. index outpaced inflation by 14.6% a year, whereas from September 2001 to September 2011, the same index gained only 0.5% a year. In other words, the U.S. exceptionalism of the last decade followed a lost decade for U.S. stocks.

To understand what drove this decade-over-decade difference in U.S. equity market returns, we can decompose the stock market’s performance into two components: the index’s fundamental return and its change in valuations. Changes in valuations are observable, and their contribution to performance is straightforward to calculate. While many investors will look at the price-earnings ratio, we prefer to use a composite valuation metric that compares price to standard accounting values (sales, gross profits, and book value), smoothed earnings (a 10-year, inflation-adjusted average), and our proprietary measure of book value.(3) The fundamental return is calculated as a residual: it’s the index total return after accounting for changes in valuations.

One can think of the fundamental return as the return generated by the companies in the index. It comes from two sources: First, there’s growth from the reinvestment of retained earnings. Second, there’s concentration of ownership that occurs when investors reinvest dividends or the company buys back stock. These two factors – growth and reinvestment of income – are the long-term drivers of equity market performance.

As Exhibit 2 shows, the difference between the U.S. market experiencing a lost decade from September 2001 to September 2011 and an exceptional decade over the subsequent 10 years is almost entirely attributable to changes in valuations. During the earlier period, valuation declines of 3.9% a year nearly negated the 4.4% fundamental return that companies delivered during that time. In the more recent period, fundamental performance was slightly better at 4.8% annualized, while valuations gained 9.8% a year. So, of the 14.1% improvement in annualized returns delivered by the U.S. market in the most recent decade relative to the decade before, 13.7% came from changes in valuations and only 0.4% came from changes in the returns delivered by the companies comprising the index.

Exhibit 2: U.S. fundamental performance has NOT been exceptional

Changes in multiples can be the difference between exceptional and lost decades

Source: MSCI U.S. index, GMO analysis. Fundamentals are an average of sales, gross profits, smoothed earnings, and GMO’s Economic Book Value.

Multiple expansion of nearly 10% a year for 10 years resulted in valuations more than doubling. For example, the index increased from a multiple of 17x 10-year average real earnings on September 30, 2011 to 37x on September 30, 2021. 

Why is the market now willing to pay such higher multiples for U.S. companies when the companies themselves look to be delivering fundamental returns that are more or less the same as they delivered in the prior decade? Lower interest rates are a natural culprit, although if low interest rates were the sole driver of high equity market valuations, one would expect to see much higher valuations in Europe and Japan. The argument for high U.S. valuations tends to come down to a belief that American companies are special – the only winners in a world of losers.

Japan’s fundamental performance outpaced the U.S.

Just how special was the 4.8% fundamental return generated by U.S. companies over the last 10 years? The answer depends on how the result is framed. For example, our team uses a range of 4.5% to 5.7% real as its estimate of expected equilibrium equity returns.(4) From this vantage point, recent U.S. fundamental performance hasn’t been special at all; it has been perfectly normal. However, when compared to fundamental performance from non-U.S. companies over the same period of only 3.3%, the U.S. result looks quite good indeed (see Exhibit 3). In the context of negative real yields on high-quality fixed income and sub-normal performance from overseas competitors, one can understand why investors would be tempted to apply a premium valuation to U.S. companies that continued to deliver historically normal fundamental results.

Exhibit 3: U.S. fundamental performance has been rather normal

Non-U.S. companies have generated sub-par fundamental returns

Source: MSCI, GMO analysis. Fundamentals are an average of sales, gross profits, smoothed earnings, book value, and GMO’s Economic Book Value.

When we disaggregate the rest of the world into regions, however, the argument that the market is rationally paying up for the sole source of normal fundamental performance becomes challenged. Corporate performance across the Emerging Markets (EM) and MSCI’s EAFE ex-Japan index (mostly comprising European companies) has averaged 3% a year for the last 10 years. Over the same period, however, fundamental performance in Japan has been 5.4% annually. Not only has Japan produced what we would consider to be normal fundamental performance over this period, Japanese companies have outperformed American companies (see Exhibit 4).

Exhibit 4: Fundamental performance by region

Emerging Markets and Europe have disappointed, but Japan outperformed the U.S.

Source: MSCI, GMO analysis. Fundamentals are an average of sales, gross profits, smoothed earnings, book value, and GMO’s Economic Book Value.

If investors are rewarding fundamental winners with high valuations, has Japan seen the same multiple expansion that we’ve seen in the U.S.? No. And that’s not because Japan started at a particularly high multiple 10 years ago: both Japan and the U.S. traded at around 17x cyclically adjusted earnings in September 2011. The difference comes from current valuations. Japan today trades at about two-thirds the valuation of the U.S. market despite Japanese companies delivering best in class fundamental returns over the prior decade (see Exhibit 5).

Exhibit 5: The price of normalcy

Japan has delivered U.S.-like fundamental performance, but trades at a significant discount.

Source: MSCI, GMO analysis

Why hasn’t Japan re-rated along with the U.S. over the past few years? We suspect the answer has something to do with what Robert Shiller refers to as Narrative Economics. Shiller argues that the stories investors tell themselves influence market pricing and behaviour. Think of the narratives that come to mind when considering Japan’s economy and corporate sector. Lost decades. Bloated balance sheets. Poor profitability. Stakeholder, not shareholder, capitalism. Who wants to rocket-ship that market to the moon? No one. It’s easier to create a narrative that the recently strong Japanese fundamental performance was just a fluke than it is to consider that perhaps Japanese companies have quietly performed quite well for longer than one might have realized.

Contrary to popular narratives, Japanese fundamentals have been on par with the U.S – and consistent with our estimates of equilibrium – for most of the last 20 years. Exhibit 6 plots fundamental performance for Japan and the U.S. over rolling 10-year periods from January 1990 to September 2021. The first data point, marked 2000 on the chart, shows that Japanese companies didn’t deliver any fundamental gains in the 1990s. Periods such as 1994-2004 saw Japanese companies destroy fundamental value. By mid-2006, however, corporate Japan was back to breakeven on a 10-year basis, and it hasn’t looked back.(5) Indeed, since September 2011, Japan’s 10-year fundamental performance has been better than the U.S. in just over half of our monthly measurements and above our lower bound for normal (4.5% real) two-thirds of the time. It seems Japan’s “lost decades” ended decades ago.

Exhibit 6: Japan has already changed

Lost decades ended decades ago

Source: MSCI, GMO analysis. Fundamentals are an average of sales, gross profits, smoothed earnings, book value, and GMO’s Economic Book Value.

It’s as easy to conjure up a story of U.S. exceptionalism as it is to assume Japanese malaise. The U.S. market, after all, includes some truly amazing businesses. For example, Apple, Amazon, Microsoft, Google, and Facebook (the “Big Five”) generated annualised fundamental performance of 16.3% over the last 10 years. Companies that can reinvest capital at high rates for long periods of time deserve to trade at higher multiples, and many investors seem to assume that the strong growth of these dominant companies justifies the premium multiple applied to the U.S. market. 

The problem with that narrative is not that these five companies don’t deserve their valuations.(6) The problem is that when you look at the U.S. market excluding these five names, its fundamental return was only 4.2% annualised over the last decade. That’s less than what we consider normal and, coincidentally, halfway between the superior performance of Japan and the disappointing results from EAFE ex-Japan and EM. Yet, the U.S. market excluding the Big Five still traded at a 32.5x CAPE at the end of September, a 30% premium to Japan. Outside of the Big Five, U.S. equity market investors are paying exceptional prices for quite dull fundamental performance.

While narratives can matter in the short term, valuations and fundamentals will matter for the long term. For investors who want to invest in companies that have generated attractive fundamental performance over the last decade, both the U.S. and Japan fit the bill. For investors who care about the price they pay for such fundamentals, Japan appears to offer a clear advantage.

Europe and EM are poised to benefit from mean reversion

What should we make of the lackluster fundamental performance over the last 10 years from companies in EAFE ex-Japan and EM regions? Do their stocks deserve a place in investors’ portfolios? We think so.

History suggests that regions and countries experience mean reversion in their fundamental performance. Economic intuition suggests the same, as competitive capitalism should cause capital to flee areas of low return (thereby improving the prospects for the capital that remains) and seek out areas of high return (thereby dampening the prospects for all). Unfortunately, our ability to look for mean reversion of regional fundamentals from decade to decade is limited by data availability, especially in EM.(7) 

To relax this constraint, we turned to the data for individual countries to see what we could learn. Regressing fundamental returns in one decade against fundamental returns in the prior decade for 37 countries with data spanning from the 1970s to the 2010s, we found a negative relationship (see Exhibit 7). That is, the lower a country’s fundamental performance was in one decade, the higher it tended to be in the subsequent decade. This isn’t the strongest relationship one may ever see,(8) but if it holds, one might expect these regions to deliver fundamental performance over the coming decade that’s consistent with our equilibrium assumptions.

Exhibit 7: Mean reversion at work

Fundamentals have been negatively correlated decade-over-decade.

Source: MSCI, GMO analysis. 37 countries; 1970s–2010s. Fundamentals are an average of sales, gross profits, smoothed earnings, book value, and GMO’s Economic Book Value.

While it’s no guarantee that the companies in these regions will be the fundamental winners of the 2020s, what is clear to us is that their current valuations are the lowest across regions as we look at markets today. And lower valuations provide better starting points for long-term performance, in part because shareholders reinvest cash flows at higher yields. Today, EAFE-ex Japan markets are priced at a 40% discount to the U.S. market, and EM trade at less than half the CAPE of the U.S. (see Exhibit 8). With reasonable prospects for improving fundamentals and the most attractive starting valuations, we think investors will reap rewards from owning the laggards of the last 10 years.

Exhibit 8: U.S. stocks trade at a significant premium

Source: MSCI, GMO analysis

Vertical axis truncated at 60; Japan’s P/E 10 peaked at over 76x in January 2006.Non-U.S. Equity Markets Offer Multiple Ways to Win

While the U.S. stock market has been far and away the leading equity market over the past decade, U.S. companies played second fiddle to Japanese companies when it came to generating fundamental returns over the period. Fundamental returns, which come in the form of growth from retained earnings and increased ownership from the reinvestment of shareholder distributions, represent the long-term drivers of equity market performance. On this metric, Japan and the U.S. have performed quite similarly not just over the last 10 years, but also the 10 years prior. 

The same cannot be said for companies in EAFE ex-Japan and EM, where fundamentals over the last decade were disappointing. History and economic intuition suggest, however, that improved fundamental performance over the next 10 years is not just possible for these regions, but probable. On the other metric that matters for equity market performance – changes in valuation multiples – the U.S. stands out. Multiple expansion has accrued to the benefit of U.S. shareholders over the last 10 years, leaving developed non-U.S. companies trading around two-thirds of the valuation of the U.S. and EM at less than half the price. 

With Japan looking capable of sustaining its fundamental performance and the rest of the non-U.S. world poised for improvement, and with non-U.S. markets much more attractively priced than U.S. stocks, we continue to believe equity investors will be rewarded for allocating as much of their equity exposure to non-U.S. markets as their risk tolerance allows. We are.(9)

Exhibit 9: Global all country equity allocation strategy (as at 31/10/2021)

Source: GMO

*Active weighting decisions are based on security level holdings and are subject to change without notice. The information is based on a representative account in the Strategy selected because it has the fewest restrictions and best represents the implementation of the Strategy. The groups indicated represent exposures determined pursuant to proprietary methodologies and are subject to change over time. Quality is predominantly U.S. but does hold some Developed ex-U.S. and Emerging. Totals may not add due to rounding. Cash is excluded for purposes of benchmark comparison. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

Learn more

Stay up to date with all of our investment insights and ideas by clicking the follow button below and you'll be notified every time we post a wire. For more information on GMO, please visit our website.

Footnotes

(1) See GMO’s 2Q 2021, 1Q 2021, and 3Q 2020 Quarterly Letters.

(2) We’ll use real, or inflation-adjusted, returns exclusively in the rest of this piece.

(3) Unlike 12-month earnings, which can be volatile and cyclical, our composite of fundamentals provides a reasonably smooth representation of the evolving earnings power of the companies comprising a given market. GMO’s proprietary measure of book value adjusts for certain expenditures that we think are more appropriately accounted for as investments that should be amortized over multi-year periods.

(4) Equilibrium equity returns are those we would expect to receive when stocks are fairly valued (i.e., no expectations of gains or losses from valuation changes). The 5.7% estimate comes from our traditional “Mean Reversion” forecast scenario and is consistent with a long view of history. The 4.5% estimate comes from our “Partial Mean Reversion” or lower-returns-for-longer scenario.

(5) Many, including our colleague Drew Edwards who manages GMO’s dedicated Japan equity strategies, credit former Prime Minister Abe with policy changes that fostered improved corporate performance. No doubt Abe’s policies helped. This chart makes clear, however, that by the time Abe was re-elected prime minister in 2012, corporate fundamentals were already improving. Timing might not be everything, but it helps! Investors interested in direct allocations to Japanese stocks can learn more about Drew’s strategies at gmo.com.

(6) I’m not making the argument that these stocks are cheap. I’m making a weaker argument that you don’t need to assume that they’re expensive to question the valuation of the U.S. market.

(7) We ran a similar analysis for the 9.25-year period from June 2002 to September 2011. During that time, companies in EAFE ex-Japan produced respectable annualized fundamental performance of 4.7% and companies in EM returned 9.6% annualized. That EM companies were outperforming during that period should come as no surprise to those of us who were being told how important it was that we buy the BRICs during much of that time.

(8) The R-squared is around 12%.

(9) Our Global All Country Equity Allocation Strategy, which represents the purest representation of our equity views, is maximally underweight the U.S.; has a dedicated allocation to Japan within its developed non-U.S. equity holdings; and is overweight Emerging Markets, mostly outside of China. Consistent with our recent writings, we’re biased toward value stocks across all geographies.